Pacific Biosciences of California, Inc.
PACB- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001299130
In the last 90 days, Pacific Biosciences of California, Inc. insiders filed 0 open-market purchases and 1 sale; 223 institutions reported holding it in 13F filings for Q2 2026, worth $320.8M in total; superinvestors ARK Invest and HHLR Advisors (Hillhouse) hold it.
Q3 2022 vs. Q2 2022
How the institutions holding Pacific Biosciences of California, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Of which not filed for Q3 2022 | Q3 2022 | Change |
|---|---|---|---|---|
| Holders | 230 | 1 | 227 | −2 |
| Shares | 225.5M | 760 | 211.8M | −13.7M (−6.1%) |
| Value | $1.03B | $3.00K | $1.23B | +$201.9M (+19.6%) |
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so the changes leave them out.
New holders (39)
Institutions that held Pacific Biosciences of California, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
Sold out (41)
Institutions that held Pacific Biosciences of California, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
Not filed for Q3 2022 yet (1)
Institutions that held Pacific Biosciences of California, Inc. at the end of Q2 2022 and haven't filed a 13F for Q3 2022. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Brewin Dolphin Wealth Management Ltd | 760 | $3.00K |